Mamas Mamas m.mamas@keele.ac.uk
Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study
Mamas, Mamas A.
Authors
Abstract
Background
Higher medication anticholinergic burden is associated with increased risk of cardiovascular disease and cognitive decline. A mechanistic pathway has not been established. We aimed to determine whether inflammation may mediate these associations.
Methods
Participants were drawn from the European Prospective Investigation into Cancer, Norfolk cohort (40-79 years at baseline). Anticholinergic burden score (ACB) was calculated at first (1HC) (1993/97) and second (2HC) (1998/2000) health checks. Fibrinogen and C-reactive protein (CRP) were measured during 1HC and Tumour Necrosis Factor alpha (TNF-a) and interleukin 6 (IL-6) during 2HC. Cross-sectional associations between ACB and inflammatory markers were examined for both health checks. Prospective associations were also examined between 1HC ACB and 2HC inflammatory markers. Models were adjusted for age, sex, lifestyle factors, co-morbidities and medications.
Results
17,678 and 22,051 participants were included in cross-sectional analyses for CRP, and fibrinogen, respectively. 5,101 participants with data on TNF-a and IL-6 were included in the prospective analyses. Cross-sectionally, compared to ACB=0, ACB =4 was associated with higher fibrinogen, beta (95% confidence interval)=0.134 g/l (0.070, 0.199), CRP 1.175 mg/l (0.715, 1.634), IL-6 0.593 pg/ml (0.254, 0.932) and TNF-a 0.137 pg/ml (0.033, 0.241). Furthermore, a point increase in ACB was associated with a higher levels of all markers. Prospectively, compared to ACB=0, ACB =4 was associated with higher IL-6(pg/ml): 0.019 (-0.323, 0.361) and TNF-a (pg/ml): 0.202% (0.81, 0.323). In addition, a unit increase in ACB was associated with a significantly higher TNF-a and IL-6.
Conclusion
Higher ACB was associated with higher inflammatory markers. Inflammation may mediate the relationship between anticholinergic medications and adverse outcomes.
Journal Article Type | Article |
---|---|
Acceptance Date | Jan 31, 2022 |
Online Publication Date | Feb 3, 2022 |
Publication Date | 2022-07 |
Publicly Available Date | Mar 28, 2024 |
Journal | British Journal of Clinical Pharmacology |
Print ISSN | 0306-5251 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 88 |
Issue | 7 |
Pages | 3297-3306 |
DOI | https://doi.org/10.1111/bcp.15261 |
Keywords | anticholinergics; cardiovascular diseases; C-reactive protein; fibrinogen; interleukin-6; tumour necrosis factor-alpha |
Publisher URL | https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/bcp.15261 |
Files
524765.pdf
(300 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by-nc/4.0/
Brit J Clinical Pharma - 2022 - Sanghavi - Higher anticholinergic burden from medications is associated with significant.pdf
(748 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by-nc/4.0/
You might also like
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search